预约演示

China approves AstraZeneca-Daiichi Sankyo’s breast cancer therapy

2023-07-13

抗体药物偶联物上市批准临床结果临床3期

Enhertu is indicated for use in adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. Credit: Nephron / commons.wikimedia.org.

Enhertunese National Medical Products Administration has granted approvHER2-lowstraZeneca and Daiichi Sabreast canceru (trastuzumab deruxtecan) as a monotherapy to treat breast cancer.

An antibody-drug conjugate (ADC) targeting the HER2 protein, Enhertu is indicaAstraZeneca in aDaiichi SankyoeseEnhertuortrastuzumab deruxtecanIHC 1+ or IHC 2+/ISH-) breasbreast cancer

Recommended ReportsHER2 Enhertu HER2-low breast cancer

ReportsLOA and PTSR Model - Paclitaxel Trevatide in Metastatic Breast Cancer GlobalData

ReportsLOA and PTSR Model - Dovitinib Lactate in Breast Cancer GlobalData

View allCompanies IntelligenceAstraZeneTrevatideichiMetastatic Breast Cancer

These patients should have received a previous systemic treatment in the metastatic setting, or have experienced a recurrence of the condition during or within six months of receiving adjuvant chemotherapy.

The latest approval is basedDovitinibfrom Phase IBreast Cancereast04 clinical trial.

Trial data showed that the therapy reduced disease progression or the risk of death by half, and boosted median overall survival by more than six months compared with physician’s choice of chemotherapy.

In February 2023, the ADC was approved for treating priorly treated unresectable or metastatic HER2-positive breast cancer.

AstraZeneca oncology business unit executive vice-president Dave Fredrickson stated: “The results from the DESTINY-Breast04 trial show Enhertu provides a significant improvement in outcomes compared to chemotherapy for patients whose tumours are determined to be HER2-low via routine testing.

“This approval is an important advance in the way breast cancer is classified and treated in China and supports our vision to bring Enhertu to more patients worldwide.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构